Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 1, 2005, Pages 24-29

  Eshleman, Susan H ^a   Guay, Laura A ^a   Wang, Jing ^b   Mwatha, Anthony ^b   Brown, Elizabeth R ^b,c   Musoke, Philippa ^d   Mmiro, Francis ^d   Jackson, J Brooks ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

Author keywords

HIV 1; Mother to child transmission; Nevirapine; Resistance; Subtype; Uganda

Indexed keywords

NEVIRAPINE;

ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE; UGANDA; VERTICAL TRANSMISSION; VIRUS MUTATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEVIRAPINE; PHYLOGENY;

EID: 24144438597     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000174656.71276.d6     Document Type: Article

References (41)

1. Descamps D, Apetrei C, Collin G, et al. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS. 1998;12:1109-1111.
2. Apetrei C, Descamps D, Collin G, et al. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. J Virol. 1998;72:3534-3538.
3. Pieniazek D, Rayfield M, Hu DJ, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS. 2000;14:1489-1495.
4. Becker-Pergola G, Kataaha P, Johnston-Dow L, et al. Analysis of HIV-1 protease and reverse transcriptase in antiretroviral drug naive Ugandan adults. AIDS Res Hum Retroviruses. 2000;16:807-813.
5. Dumans AT, Soares MA, Machado ES, et al. Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis. 2004;189:1232-1238.
6. Brenner B, Turner D, Oliveira M, et al. AV106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17:F1-F5.
7. Kantor R, Carvalho AP, Wynhoven B, et al. Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions. Antivir Ther. 2003;8:S58.
8. Abecasis A, Gomes P, Derdelinckx I, et al. L89I/V: a novel mutation selected by protease inhibitor therapy in subtype G, but not in subtype B-infected patients. Antivir Ther. 2003;8:S140.
9. Frater AJ, Beardall A, Ariyoshi K, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS. 2001;15:1493-1502.
10. Loveday C, Burke A, van Hooff F, et al. Equivalence in virologic responses to HAART in patients with HlV-1 subtype non-B infections: a case-controlled study (n = 100). Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections. 2001; Chicago, IL. Abstract #526. February 4-8, 2001.
11. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial. Lancet. 1999;354:795-802.
12. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
13. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187:725-735.
14. Dorenbaum A. Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002;288:189-198.
15. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217-228.
16. World Health Organization. Nevirapine for the prevention of mother to child transmission of HIV. Available at: http://www.who.int/reproductivehealth/ rtis/nevirapine.html, Accessed August 2003.
17. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine (NVP) resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single dose NVP (HIVNET 012). J Acquit Immune Defic Syndr. 2004;35:126-130.
18. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951-1957.
19. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single dose NVP prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses. 2004;20:595-599.
20. Havlir DV, Eastman S, Gamst A, et al. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996;70:7894-7899.
21. Mirochnick M. Fenton T. Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J infect Dis. 1998;178:368-374.
22. Musoke P, Guay LA. Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479-486.
23. Muro E, Droste J. Hofstede HT, et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose NVP: implications for intervention studies. Paper presented at: 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA. Abstract #891. February 8-11, 2004.
24. Eshleman SH, Becker-Pergola G, Deseyve M, et al. Impact of HIV-1 subtype on women receiving single dose NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET 012). J Infect Dis. 2001;184:914-917.
25. Sullivan J. South African Intrapartum Nevirapine Trial: selection of resistance mutations. Paper presented at: XIV International Conference on AIDS; 2002; Barcelona, Spain. Abstract #LpPeB9024. July 9-12, 2002.
26. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet. 2003;362:1171-1177.
27. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis. 2005;192:30-36.
28. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
29. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
30. Sonis J. A closer look at confounders. Fam Meet. 1998;30:584-588.
31. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920-928.
32. Kantor R, Lee E, Johnston E, et al. Rapid flux in non-nucleoside reverse transcriptase mutations among subtype C HIV-1-infected women after single dose nevirapine. Antivir Ther. 2003;8:S85.
33. Collins JA, Thompson MG, Paintsil E, et al. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol. 2004;78:603-611.
34. Huang W, Wrin T, Gamarnik A, et al. RT mutations that confer NNRTI resistance may also impair replication capacity. Paper presented at: XI International HIV Drug Resistance Workshop; 2002; Seville. Spain, Abstract #72. July 2-5, 2002.
35. Gerondelis P, Archer RH, Palaniappan C, et al. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. J Virol. 1999;73:5803-5813.
36. Little SJ, Dawson K, Hellmann NS, et al. Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring therapy. Antivir Ther. 2003;8:S129.
37. Morris L, Martinson N, Pillay C, et al. Persistence of nevirapine resistance mutations 6 months following single dose nevirapine. Paper presented at; XV International AIDS Conference; 2004; Bangkok, Thailand. Abstract #ThOrB1353. July 11-16, 2004.
38. Eshleman SH, Nissley D, Claasen C, et al. Sensitive drug resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine-resistance mutation in some women and infants after single dose NVP: HIVNET 012. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston, MA. February 22-25, 2005.
39. Palmer S, Boltz V, Maldarelli F, et al. Persistence of NNRTI-resistant variants after single-dose nevirapine in HIV-1 subtype C-infected women. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston, MA. February 22-25, 2005.
40. Loubser S, Balfe P, Sherman G, et al. Sensitive real-time PCR quantification of 103N resistance mutants following single-dose treatment with nevirapine. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston, MA. February 22-25, 2005.
41. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229-240.